For more than 235 years, Takeda has been serving society with innovative medicines, helping patients reclaim valuable moments of life from illness. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

TAKEDA CEO TALKS GLOBALIZATION, INNOVATION IN PHARMACEUTICAL INDUSTRY

Northeastern University | November 30, 2016

news image

Christophe Weber, pres­i­dent and CEO of Takeda Phar­ma­ceu­tical Com­pany Ltd., brings a global vision, a mul­ti­cul­tural per­spec­tive, and a long-term approach to run­ning the 235-year-old Japanese company....

Read More

TINY OVID INKS A UNIQUE RARE DISEASE DEAL WITH DRUG GIANT TAKEDA (TKPYY)

BioSpace (a DHI Group, Inc. company) | January 18, 2017

news image

Takeda Pharmaceutical Company Limited (TSE: 4502) and Ovid Therapeutics Inc., a privately-held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the formation of a global collaboration focused on the clinical development and commercialization of Takeda’s investigational new drug TAK-935, a novel, potent and highly selective CH24H inhibitor, in rare pediatric epilepsies. TAK-935 has successfully complete...

Read More

JAPAN’S TAKEDA ACQUIRES US CANCER DRUG MANUFACTURER ARIAD FOR $5.2BN

pharmaceutical-technology | February 17, 2017

news image

Japan-based Takeda Pharmaceutical Company has completed the previously announced acquisition of American oncology company ARIAD Pharmaceuticals for $5.2bn. The acquisition was concluded through a tender offer and subsequent merger of ARIAD with Takeda Pharmaceuticals USA’s wholly owned subsidiary Kiku Merger....

Read More

TAKEDA AND MMV LAUNCH NEW PROGRAMME TO FIND LEAD COMPOUNDS FOR MALARIA TREATMENT

Pharmaceutical Technology | April 03, 2017

news image

Japanese-based Takeda Pharmaceutical Company and Medicines for Malaria Venture in Switzerland (MMV) have signed an agreement to start a new joint research programme aimed at finding lead compounds for malaria treatment....

Read More
news image

TAKEDA CEO TALKS GLOBALIZATION, INNOVATION IN PHARMACEUTICAL INDUSTRY

Northeastern University | November 30, 2016

Christophe Weber, pres­i­dent and CEO of Takeda Phar­ma­ceu­tical Com­pany Ltd., brings a global vision, a mul­ti­cul­tural per­spec­tive, and a long-term approach to run­ning the 235-year-old Japanese company....

Read More
news image

TINY OVID INKS A UNIQUE RARE DISEASE DEAL WITH DRUG GIANT TAKEDA (TKPYY)

BioSpace (a DHI Group, Inc. company) | January 18, 2017

Takeda Pharmaceutical Company Limited (TSE: 4502) and Ovid Therapeutics Inc., a privately-held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the formation of a global collaboration focused on the clinical development and commercialization of Takeda’s investigational new drug TAK-935, a novel, potent and highly selective CH24H inhibitor, in rare pediatric epilepsies. TAK-935 has successfully complete...

Read More
news image

JAPAN’S TAKEDA ACQUIRES US CANCER DRUG MANUFACTURER ARIAD FOR $5.2BN

pharmaceutical-technology | February 17, 2017

Japan-based Takeda Pharmaceutical Company has completed the previously announced acquisition of American oncology company ARIAD Pharmaceuticals for $5.2bn. The acquisition was concluded through a tender offer and subsequent merger of ARIAD with Takeda Pharmaceuticals USA’s wholly owned subsidiary Kiku Merger....

Read More
news image

TAKEDA AND MMV LAUNCH NEW PROGRAMME TO FIND LEAD COMPOUNDS FOR MALARIA TREATMENT

Pharmaceutical Technology | April 03, 2017

Japanese-based Takeda Pharmaceutical Company and Medicines for Malaria Venture in Switzerland (MMV) have signed an agreement to start a new joint research programme aimed at finding lead compounds for malaria treatment....

Read More